# Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

> **NCT01286987** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 113 (actual)

## Conditions studied

- Advanced or Recurrent Solid Tumors
- Breast Neoplasms
- Ovarian Cancer, Epithelial
- Ewing Sarcoma
- Small Cell Lung Carcinoma
- Prostate Cancer
- Pancreas Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT01286987
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-03
- **Primary completion:** 2015-03-31
- **Final completion:** 2017-01-30
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2019-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01286987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01286987, "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01286987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*